Feature Channels: Vision

• share
• favorite_border

A medicated silicone ring that rests on the surface of the eye and slowly releases medication reduced eye pressure in glaucoma patients by about 20 percent over six months. These multi-center randomized clinical trial results are the first published research on this type of continuous glaucoma drug delivery technology, which could benefit the nearly 3 million people in the United States with glaucoma. Published in Ophthalmology, journal of the American Academy of Ophthalmology.

• share
• favorite_border

Building on existing evidence, vision researchers have found that limiting exposure to blue light after sunset increases the quality and length of sleep. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

Pterostilbene (PS), a component of blueberries, have been found to protect against dry eye disease according to a new study. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

A new study has shown that Ebola survivors may be at risk of severe vision loss or blindness weeks after being declared virus-free. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

Researchers have safely transplanted stem cells derived from a patient’s skin to the back of the eye in an effort to restore vision. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

Scientists have successfully implanted a prosthesis that restores some central vision in patients with only limited peripheral vision remaining to them – the first time artificial and natural vision has ever been integrated in humans. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

Sjogren's syndrome affects an estimated four million people in the U.S., but diagnosis is often delayed because its symptoms are similar to other conditions. A new study in the American Journal of Physiology—Cell Physiology describes a protein with the potential to be an earlier and more precise indicator of the disease.

• share
• favorite_border

According to new research, injection of 3-hydroxybutyrate (3HB) offers similar protection as a low calorie diet against nerve degeneration in rats with glaucoma. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Seattle, Wash.

• share
• favorite_border

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.

• share
• favorite_border

Patients with age-related macular degeneration (AMD), the most common cause of major vision loss in older people, still show benefits from a new class of therapy -- originally developed to treat cancer -- after long-term treatment.

• share
• favorite_border

RPB President Brian F. Hofland will present an overview of investigations conducted by leaders in the fields of retinal imaging, early disease detection, and photoreceptor regeneration and transplantation. The RPB featured scientists will be present for Q&A.

• share
• favorite_border

The National Eye Institute (NEI), part of NIH, is participating in the Inaugural Press Conference from the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2016).

• share
• favorite_border

Pioneering gene therapy has restored some vision to patients with a rare form of genetic blindness for as long as four years, raising hopes it could be used to cure common causes of vision loss, new University of Oxford research published today shows.

• share
• favorite_border

The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) is the largest gathering of eye and vision researchers in the world, with over 11,000 attendees from more than 75 countries. Two free events will feature speakers highlighting recent successes — and emerging threats — facing ophthalmic clinicians and researchers around the world.

• share
• favorite_border

This ARVO Meeting showcases cutting-edge eye and vision science and an early glimpse into the latest advances in potential treatments for eye disease and blindness — often years ahead of their introduction to the clinic.

• share
• favorite_border

World-leading researchers from Queen’s University Belfast are among a team of scientists from the USA and Ireland who are collaborating to develop a novel treatment for diabetes-related blindness.

• share
• favorite_border

Feature story with patient perspective emphasizes the importance of having a comprehensive dilated eye exam, which is the best way to find out for sure if eyes are healthy.

• share
• favorite_border

Magnifying Smartphone Screen Apps For Visually Impaired, Online Anti-Bullying Programs, A One Atom Engine and more in the Technology News Source

• share
• favorite_border

Adam Gordon, O.D., discusses blue light, including the lack of clinical evidence in advertisements overstating dangers, as well as the effects of blue light on sleep and eye discomfort.

• share
• favorite_border

Children with vision problems not correctable with glasses or contact lenses may be twice as likely to have a diagnosis of attention deficit/hyperactivity disorder (ADHD), suggests a study in the May issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.